Source: Dow Jones Newswires
By: Baba, Razak Musah
08/23/2010
GlaxoSmithKline has started Phase III clinical trials of its herpes zoster vaccine. The trials will evaluate the vaccine’s efficacy, safety, and immunogenicity. Investigators are recruiting more than 30,000 patients worldwide for the study.